Hemosol B0

Hemosol B0 is a sterile aqueous electrolyte solution that contains calcium, magnesium, sodium, chloride, bicarbonate and lactate. It is supplied in a ready‑to‑use liquid form for intravenous infusion or incorporation into haemodialysis circuits. The product is marketed in the European Union and is prescribed by healthcare professionals for electrolyte management during renal replacement therapy and related clinical situations.

Hemosol B0 is indicated for clinical situations that require controlled electrolyte replacement and acid‑base balance. It is commonly employed in the following contexts:

- Renal replacement therapy, specifically haemodialysis, to provide essential cations and anions. - Intravenous electrolyte supplementation in patients with acute or chronic electrolyte disturbances. - Maintenance of plasma osmolarity during prolonged infusion therapy. - Supportive care for patients undergoing major surgery or trauma with anticipated fluid shifts. - Adjunctive therapy in critical care settings where precise electrolyte control is required.

Adverse reactions to Hemosol B0 are generally infrequent, but they can be categorized by frequency and severity.

Common: - Mild infusion site irritation or erythema. - Transient nausea or mild abdominal discomfort. - Slight increase in serum calcium or magnesium levels that resolves without intervention. - Temporary changes in blood pressure related to fluid volume shifts.

Serious: - Hyperkalemia or severe electrolyte imbalance if administered in error. - Acute pulmonary edema from rapid volume overload. - Severe allergic reaction or anaphylaxis, though rare. - Metabolic alkalosis due to excess bicarbonate administration. - Cardiac arrhythmias associated with abrupt electrolyte changes.

When using Hemosol B0, clinicians should observe several safety considerations to minimise risk. Important precautions include:

- Verify patient electrolyte status and acid‑base balance before initiation. - Adjust infusion rates in patients with compromised cardiac or pulmonary function. - Monitor serum calcium, magnesium, sodium, and bicarbonate levels regularly during therapy. - Use caution in individuals with known hypersensitivity to any component of the solution. - Ensure proper storage conditions to maintain solution sterility and stability. - Document any adverse events promptly and report according to local regulations.

Hemosol B0 may interact with other medications or solutions administered concurrently. Awareness of these interactions helps prevent complications.

Avoid: - Co‑administration with calcium channel blockers that may potentiate calcium overload. - Simultaneous infusion of high‑potassium solutions, which can exacerbate hyperkalemia. - Use with acidic drug formulations that could precipitate when mixed with bicarbonate.

Use with caution: - Concurrent use of diuretics that alter sodium or magnesium balance. - Administration alongside other intravenous fluids containing overlapping electrolytes. - Patients receiving anticoagulants, as rapid volume shifts may affect hemodynamics. - Situations where rapid correction of acidosis is required, to avoid over‑correction.